Latham & Watkins represented the initial purchasers in the offering while Cooley advised Cytokinetics. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, has announced the pricing of its […]
Cytokinetics’ $540 Million Convertible Senior Notes Offering
Blueprint Medicines Corporation’s Financing Collaborations with Sixth Street and Royalty Pharma
Goodwin Procter advised Blueprint Medicines Corporation on the deal while Cooley represented Sixth Street. Blueprint Medicines Corporation (NASDAQ: BPMC) announced its strategic financing collaborations with Sixth […]
Biote’s Business Combination Agreement with Haymaker Acquisition Corp.
Cooley advised Biote on the deal. Biote, a medical practice-building business within the hormone optimization space, announced its definitive business combination agreement with special purpose acquisition company […]
Pfizer’s $6.7 Billion Acquisition of Arena Pharmaceuticals
Ropes & Gray advised Pfizer Inc. in the deal, while Cooley represented Arena Pharmaceuticals. Debevoise & Plimpton advised Evercore Group and Guggenheim Securities as financial advisors […]
Boston Scientific’s $1.75 Billion Acquisition of Baylis Medical Company
Shearman & Sterling advised Boston Scientific Corporation on the acquisition of Baylis Medical Company, assisted by BCF Business Law, in collaboration with Cooley LLP (U.S. lead […]
ZOLL Medical’s $538 Million Acquisition of Itamar Medical
Latham & Watkins and Goldfarb Seligman & Co. represented Itamar Medical in the transaction. Cooley and Gornitzky & Co. advised ZOLL Medical. Itamar™ Medical Ltd. (Nasdaq […]
Bayer AG’s Acquisition of Vividion Therapeutics
Cooley and Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics on the deal. Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally […]
Lyell Immunopharma’s $425 Million Initial Pubic Offering
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company […]